2-羟基-5-(甲基硫代)苯甲酸 | 32318-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-羟基-5-(甲基硫代)苯甲酸
• 英文名称: 2-hydroxy-45-methylsulfanylbenzoic acid
• 英文别名: 2-hydroxy-5-(methylthio)benzoic acid；5-methylthiosalicylic acid；2-hydroxy-5-methylsulfanyl-benzoic acid；2-Hydroxy-5-methylmercapto-benzoesaeure；5-Methylmercapto-salicylsaeure；2-hydroxy-5-(methylthio)-benzoic acid；2-Hydroxy-5-(methylsulfanyl)benzoic acid；2-hydroxy-5-methylsulfanylbenzoic acid
• CAS: 32318-42-6
• 化学式: C₈H₈O₃S
• 分子量: 184.216
• InChiKey: DATDARDTUZHWMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  82.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2930909090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 5-(Methylthio)salicylic acid, 98%
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 32318-42-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C8H8O3S
Molecular Weight : 184,21 g/mol
CAS-No. : 32318-42-6
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
5-(Methylthio)salicylic acid, 98%
Skin Irrit. 2; Eye Irrit. 2; STOT -
SE 3; H315, H319, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
5-(Methylthio)salicylic acid, 98%
Xi, R36/37/38 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Sulphur oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 123 - 124 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents, Strong bases
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-羟基-5-(甲基硫代)苯甲酸 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以86%的产率得到2-hydroxymethyl-4-methylsulfanylphenol
  参考文献：
  名称：

  Imidazole Inhibitors of Cytokine Release:  Probing Substituents in the 2 Position

  摘要：

  Novel 2,4,5-trisubstituted imidazole derivatives were prepared as potential anticytokine agents. Thirty-seven compounds were tested on their ability to inhibit the release of tumor necrosis factor-a (TNF-alpha and interleukin-1beta (IL-beta) from peripheral blood mononuclear cells (PBMC) or human whole blood. SARs (structure activity relationships) for substituents-at the 4 and 5 position of the imidazole core were similar to those described for other inhibitors of cytokine. release and p38 MAP (mitogen-activated protein) kinase. Starting from benzylsulfanyl imidazole 2b (IC50 p(38), 4.0 muM; TNF-alpha, 1.1,muM; IL-1beta, 0.38,muM), the contribution of substituents at the 2 Position to enzyme inhibitory and cellular activity of test compounds was investigated. This strategy led to the identification of compound 2q (IC50 p38, 0.63 muM; TNF-alpha, 0.90 muM; IL-1beta, 0.04,muM), which was 6-10 times more potent than the initial lead 2b with respect to inhibition of p38 and IL-1beta release and equipotently inhibited TNF-alpha release.

  DOI：

  10.1021/jm020873z
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 作用下， 生成 2-羟基-5-(甲基硫代)苯甲酸
  参考文献：
  名称：

  Stewart, Journal of the Chemical Society, 1922, vol. 121, p. 2558

  摘要：

  DOI：

文献信息

• Cis-imidazolines
  申请人：Fotouhi Nader

  公开号：US20060211693A1

  公开（公告）日：2006-09-21

  There are presented compounds of the formula or pharmaceutically acceptable salts thereof, wherein Y 1 , Y 2 , X 1 , X 2 , X 3 and R are as described in this application. These compounds are believed to inhibit MDM2-p53 interaction and as such the compounds will have anti-hyperproliferative cellular activity.

  提供了以下公式化合物或其药用可接受的盐， 其中Y1、Y2、X1、X2、X3和R如本申请所述。据信这些化合物能够抑制MDM2-p53相互作用，因此这些化合物将具有抗高增殖细胞活性。
• Process for preparing dibenzothiazepine compounds
  申请人：Murray Michael Paul

  公开号：US20070203336A1

  公开（公告）日：2007-08-30

  A dibenzothiazepine compound is suitably prepared by subjecting a 2-amino-2′-carboxy-diphenylsulfide compound to dehydration-condensation reaction in the presence of an acidic catalyst; the 2-amino-2′-carboxy-diphenylsulfide compound is suitably prepared by reducing a 2-nitro-2′-carboxy-diphenylsulfide compound in a lower aliphatic ester solvent; and the 2-nitro-2′-carboxy-diphenylsulfide compound is suitably prepared by reacting a nitrobenzene compound with a thiosalicylic acid compound in a mixture of a lower aliphatic alcohol and water.

  通过在酸性催化剂的存在下，将2-氨基-2'-羧基二苯硫醚化合物进行脱水缩合反应，可以适当地制备二苯并噻吩类化合物；2-氨基-2'-羧基二苯硫醚化合物可以通过在较低的脂肪酯溶剂中还原2-硝基-2'-羧基二苯硫醚化合物来适当地制备；而2-硝基-2'-羧基二苯硫醚化合物可以通过在较低脂肪醇和水的混合物中，将硝基苯化合物与硫代水杨酸类化合物反应来适当地制备。
• [DE] 2-THIO-SUBSTITUIERTE IMIDAZOLDERIVATE UND IHRE VERWENDUNG IN DER PHARMAZIE<br/>[EN] 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE IN PHARMACEUTICS<br/>[FR] DERIVES D'IMIDAZOL 2-THIO-SUBSTITUES ET LEUR UTILISATION DANS LE DOMAINE PHARMACEUTIQUE
  申请人：MERCKLE GMBH

  公开号：WO2004018458A1

  公开（公告）日：2004-03-04

  Die Erfindung betrifft 2-Thio-substituierte Imidazolderivate der Formel (I) worin die Reste R1, R2, R3 und m die in der Beschreibung angegebene Bedeutung besitzen. Die erfindungsgemässen Verbindungen besitzen eine immunmodulierende und/oder die Cytokinfreisetzung hemmende Wirkung und sind daher geeignet zur Behandlung von Erkrankungen, die mit einer Störung des Immunsystems im Zusammenhang stehen.

  这项发明涉及式(I)的2-硫代取代咪唑衍生物，其中残基R1、R2、R3和m具有描述中所指定的含义。根据本发明的化合物具有免疫调节和/或细胞因子释放抑制作用，因此适用于治疗与免疫系统紊乱相关的疾病。
• New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them
  申请人：Auvin Serge

  公开号：US20050261269A1

  公开（公告）日：2005-11-24

  Novel derivatives of amidines of formula wherein the substituents are defined as in the specification which are useful for inhibiting activity on NO-synthase enzymes producing nitrogen mono oxide and/or trapping the reactive oxygen species (ROS) making them useful for treating various diseases.

  该项发明涉及公式中所定义的取代基的新型氨基甲酸酰胺衍生物，其对产生一氧化氮的NO合酶酶活性具有抑制作用，并且对于捕获反应性氧化物种（ROS）也具有作用，因此对于治疗各种疾病是有用的。
• Process for preparing dibenzothiazepine derivatives
  申请人：Harada Katsumasa

  公开号：US20060173178A1

  公开（公告）日：2006-08-03

  A process for preparing a dibenzothiazepine derivative such as dibenzo[b,f][1,4]thiazepin-11-one employable as a starting material for the preparation of 11-[4-(2-(2-hydroxyethoxy)ethyl)]-1-piperadinyldibenzothiazepine derivative which is known to be effective as an antipsychotic pharmaceutical, has the steps of reacting a nitrobenzene derivative with a thiosalicylic acid derivative, reducing the obtained 2-nitro-2′-carboxy-diphenylsulfide derivative, and subjecting the obtained 2-amino-2′-carboxy-diphenylsulfide derivative to dehydration-condensation reaction.

  一种制备二苯并噻吩衍生物的方法，例如二苯并[b，f][1,4]噻吩-11-酮，可用作制备11-[4-(2-(2-羟乙氧基)乙基)]-1-哌嗪基二苯并噻吩衍生物的起始物质，该衍生物已知对抗精神病药物有效，包括以下步骤：将硝基苯衍生物与硫氧化水杨酸衍生物反应，还原所得的2-硝基-2'-羧基二苯基硫醚衍生物，并将所得的2-氨基-2'-羧基二苯基硫醚衍生物进行脱水缩合反应。